On January 17, 2023 Hengrui Medicine reported that recently, the company’s SHR2554 tablets were proposed to be included in the list of breakthrough therapeutic varieties by the Drug Evaluation Center of the State Drug Administration, and the publicity period will be 7 days (Press release, Hengrui Pharmaceuticals, JAN 17, 2023, View Source [SID1234633514]). SHR2554 tablet is a new, highly effective and selective oral EZH2 inhibitor developed by the company, which is intended for the treatment of malignant tumors. Up to now, about 89.38 million yuan has been invested in the research and development of SHR2554 related projects.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!